View Financial HealthSynbio Tech 배당 및 자사주 매입배당 기준 점검 3/6Synbio Tech 수익으로 충분히 충당되는 현재 수익률 5.88% 보유한 배당금 지급 회사입니다.핵심 정보5.9%배당 수익률-10.2%자사주 매입 수익률총 주주 수익률-4.3%미래 배당 수익률n/a배당 성장률24.0%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향69%최근 배당 및 자사주 매입 업데이트Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.공시 • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.모든 업데이트 보기Recent updatesReported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.39 (vs NT$1.26 in 1Q 2025)First quarter 2026 results: EPS: NT$0.39 (down from NT$1.26 in 1Q 2025). Revenue: NT$214.5m (down 8.2% from 1Q 2025). Net income: NT$13.3m (down 66% from 1Q 2025). Profit margin: 6.2% (down from 17% in 1Q 2025). The decrease in margin was primarily driven by lower revenue.Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to NT$58.50. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to NT$59.80. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.Reported Earnings • Mar 15Full year 2025 earnings released: EPS: NT$5.29 (vs NT$5.43 in FY 2024)Full year 2025 results: EPS: NT$5.29. Revenue: NT$1.04b (up 5.0% from FY 2024). Net income: NT$176.0m (up 3.4% from FY 2024). Profit margin: 17% (in line with FY 2024).Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.공시 • Mar 12Synbio Tech Inc., Annual General Meeting, May 29, 2026Synbio Tech Inc., Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanBuy Or Sell Opportunity • Mar 11Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to NT$69.60. The fair value is estimated to be NT$87.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 26%.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Director Zhao-Ming Liu was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$99.2m).New Risk • Nov 12New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.2% average weekly change).Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.92 (vs NT$1.81 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.92 (down from NT$1.81 in 3Q 2024). Revenue: NT$211.3m (down 23% from 3Q 2024). Net income: NT$31.8m (down 44% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$131, the stock trades at a trailing P/E ratio of 24.9x. Average forward P/E is 22x in the Biotechs industry in Taiwan. Total returns to shareholders of 64% over the past year.Reported Earnings • Aug 12Second quarter 2025 earnings released: EPS: NT$1.92 (vs NT$1.74 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.92 (up from NT$1.74 in 2Q 2024). Revenue: NT$309.1m (up 28% from 2Q 2024). Net income: NT$62.6m (up 15% from 2Q 2024). Profit margin: 20% (down from 23% in 2Q 2024). The decrease in margin was driven by higher expenses.New Risk • Jul 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk High level of debt (42% net debt to equity).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$2.57b market cap, or US$86.0m).공시 • May 08Synbio Tech Inc. has filed a Follow-on Equity Offering.Synbio Tech Inc. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 2,122,000 Price(minimum): TWD 46.31 Security Name: Shares Security Type: Common Stock Securities Offered: 560,000 Price\Range: TWD 56.5 Transaction Features: Subsequent Direct ListingNew Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$1.93b market cap, or US$58.3m).공시 • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.62b market cap, or US$80.9m).공시 • Apr 05Synbio Tech Inc., Annual General Meeting, Jun 27, 2024Synbio Tech Inc., Annual General Meeting, Jun 27, 2024.공시 • Apr 04SYNPET, Subsidiary Brand of SYNBIO TECH Announces to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024SYNPET, a subsidiary brand of SYNBIO TECH announced its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will take place from April 29, 2024 to May 1, 2024 at the Kansas City Convention Center in Kansas City, Missouri, USA. At Petfood Forum 2024, SYNPET will showcase its headlining product: GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior. Produced through lactic acid bacteria fermentation, SYNPET's GABA has high bioavailability and boasts a purity over 20%, offering stability for easy processing into various formats such as capsules, powder, and pet food formulations.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 1295 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: 1295 의 배당금 지급이 증가했지만 회사는 2 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Synbio Tech 배당 수익률 vs 시장1295의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1295)5.9%시장 하위 25% (TW)1.4%시장 상위 25% (TW)5.0%업계 평균 (Biotechs)0.6%분석가 예측 (1295) (최대 3년)n/a주목할만한 배당금: 1295 의 배당금( 5.88% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.42% )보다 높습니다.고배당: 1295 의 배당금( 5.88% )은 TW 시장( 5% )주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 69% )을 통해 1295 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 1295 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:57종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Synbio Tech Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hsiu Chi LinMasterlink Securities Investment Advisory
Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
공시 • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.
Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.39 (vs NT$1.26 in 1Q 2025)First quarter 2026 results: EPS: NT$0.39 (down from NT$1.26 in 1Q 2025). Revenue: NT$214.5m (down 8.2% from 1Q 2025). Net income: NT$13.3m (down 66% from 1Q 2025). Profit margin: 6.2% (down from 17% in 1Q 2025). The decrease in margin was primarily driven by lower revenue.
Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to NT$58.50. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.
Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to NT$59.80. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.
Reported Earnings • Mar 15Full year 2025 earnings released: EPS: NT$5.29 (vs NT$5.43 in FY 2024)Full year 2025 results: EPS: NT$5.29. Revenue: NT$1.04b (up 5.0% from FY 2024). Net income: NT$176.0m (up 3.4% from FY 2024). Profit margin: 17% (in line with FY 2024).
Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
공시 • Mar 12Synbio Tech Inc., Annual General Meeting, May 29, 2026Synbio Tech Inc., Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
Buy Or Sell Opportunity • Mar 11Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to NT$69.60. The fair value is estimated to be NT$87.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 26%.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Director Zhao-Ming Liu was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$99.2m).
New Risk • Nov 12New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.2% average weekly change).
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.92 (vs NT$1.81 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.92 (down from NT$1.81 in 3Q 2024). Revenue: NT$211.3m (down 23% from 3Q 2024). Net income: NT$31.8m (down 44% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$131, the stock trades at a trailing P/E ratio of 24.9x. Average forward P/E is 22x in the Biotechs industry in Taiwan. Total returns to shareholders of 64% over the past year.
Reported Earnings • Aug 12Second quarter 2025 earnings released: EPS: NT$1.92 (vs NT$1.74 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.92 (up from NT$1.74 in 2Q 2024). Revenue: NT$309.1m (up 28% from 2Q 2024). Net income: NT$62.6m (up 15% from 2Q 2024). Profit margin: 20% (down from 23% in 2Q 2024). The decrease in margin was driven by higher expenses.
New Risk • Jul 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk High level of debt (42% net debt to equity).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$2.57b market cap, or US$86.0m).
공시 • May 08Synbio Tech Inc. has filed a Follow-on Equity Offering.Synbio Tech Inc. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 2,122,000 Price(minimum): TWD 46.31 Security Name: Shares Security Type: Common Stock Securities Offered: 560,000 Price\Range: TWD 56.5 Transaction Features: Subsequent Direct Listing
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$1.93b market cap, or US$58.3m).
공시 • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.62b market cap, or US$80.9m).
공시 • Apr 05Synbio Tech Inc., Annual General Meeting, Jun 27, 2024Synbio Tech Inc., Annual General Meeting, Jun 27, 2024.
공시 • Apr 04SYNPET, Subsidiary Brand of SYNBIO TECH Announces to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024SYNPET, a subsidiary brand of SYNBIO TECH announced its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will take place from April 29, 2024 to May 1, 2024 at the Kansas City Convention Center in Kansas City, Missouri, USA. At Petfood Forum 2024, SYNPET will showcase its headlining product: GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior. Produced through lactic acid bacteria fermentation, SYNPET's GABA has high bioavailability and boasts a purity over 20%, offering stability for easy processing into various formats such as capsules, powder, and pet food formulations.